Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomised Study on Liposomal Cytarabine (DepoCyte) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol.

Trial Profile

Phase III Randomised Study on Liposomal Cytarabine (DepoCyte) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol.

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Asparaginase; Dexamethasone; Mercaptopurine; Methotrexate; Prednisolone sodium succinate
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2020 Results of an analysis from following clinical trials: Dutch: DCOG-ALL10/11 trials, Australian: ANZCHOG-ALL8 and AIEOP-BFM-ALL2009 trials, UK: ALL2003 trial and NOPHO-ALL2008 trial assessing association between Down syndrome and clinical outcome presented at the 25th Congress of the European Haematology Association
    • 02 May 2016 This trial is 'prematurely ended' in Lithuania, according to European Clinical Trials Database.
    • 17 Mar 2012 Additional location (Lithuania) added and additional lead trial centre identified as reported by European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top